866-997-4948(US-Canada Toll Free)

Hepatitis B - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Sep 2010

Category :

Therapeutic Area

No. of Pages : 41 Pages


GlobalData, the industry analysis specialist, has released its new report, Hepatitis B Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global Hepatitis B therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Hepatitis B sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

GlobalData estimates the global Hepatitis B (Hepatitis B) therapeutics market to be valued at $1.3bn in 2009. The market is estimated to grow up to $1.5bn in 2017, with a compound annual growth rate (CAGR) of 1.3%. This slow growth is attributed to the patent expiry of Baraclude in 2015. Growth in the Hepatitis B market will be driven by the increase in the number of patients. The US is the largest market for Hepatitis B and it contributes to approximately 50% of the global market

Scope

The scope of the report includes:

  • Annualized global Hepatitis B therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017. 
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include nucleoside analogs, nucleotide analogs, interferons and glucocorticoids.
  • Analysis of the current and future market competition in the global Hepatitis B therapeutics market. The key future market players covered are Novartis, Gilead Sciences, Bristol Meyers Squibb, Hoffmann-La Roche Inc., Cytheris SA, LG Life Sciences Ltd, Enzo Biochem, Digna Biotech, Daewoong Pharma and IRX Therapeutics. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the Hepatitis B market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Hepatitis B therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global Hepatitis B therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the global Hepatitis B therapeutics market landscape? Identify, understand and capitalize.
Table Of Contents

1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4

2 Hepatitis B: Introduction 5
2.1 GlobalData Pipeline Report Guide 5

3 Hepatitis B: Market Characterization 6
3.1 Overview 6
3.2 Hepatitis B Therapeutics Market Size 6
3.3 Hepatitis B Therapeutics Market Forecast and CAGR 7
3.4 Drivers and Barriers for the HBV Market 8
3.4.1 Drivers of the HBV Market 8
3.4.2 Barriers for the Hepatitis B Therapeutics Market 8
3.5 Opportunity and Unmet Need 9
3.6 Key Takeaway 10

4 Hepatitis B Therapeutics Market: Competitive Assessment 11
4.1 Overview 11
4.2 Strategic Competitor Assessment 11
4.3 Product Profile for the Major Marketed Products in the Hepatitis B Therapeutics Market 13
4.3.1 Baraclude (Entecavir) 13
4.3.2 Viread (Tenofovir) 14
4.3.3 Tyzeka (Telbivudine) 15
4.3.4 Hepsera (Adefovir Dipivoxil) 16
4.3.5 Epivir-HBV (lamivudine) 17
4.3.6 Pegasys 17
4.4 Key Takeaway 18

5 Hepatitis B: Pipeline Assessment 19
5.1 Overview 19
5.2 Strategic Pipeline Assessment 19
5.2.1 Technology Trends Analytic Framework 19
5.3 Hepatitis B Therapeutics Promising Drugs under Clinical Development 21
5.4 Drugs under Clinical Development 21
5.4.1 Entecavir plus Adefovir combination therapy 21
5.4.2 Tenofovir plus Emtricitabine combination therapy 22
5.4.3 Pegylated Interferon Alfa-2a + Adefovir 22
5.5 Hepatitis B Therapeutics Market Clinical Pipeline by Mechanism of Action 23
5.6 Hepatitis B Therapeutics Pipeline Pipeline by Clinical Phases of Development 24
5.6.1 Hepatitis B Therapeutics Phase III Clinical Pipeline 24
5.6.2 Hepatitis B Therapeutics Phase II Clinical Pipeline 25
5.6.3 Hepatitis B Therapeutics Phase I Clinical Pipeline 25
5.6.4 Hepatitis B Therapeutics Preclinical Pipeline 26
5.7 Discontinued / Suspended Drugs for Hepatitis B 26
5.8 Key Takeaway 26

6 Hepatitis B therapeutics market: Implications for Future Market Competition 27

7 Hepatitis B Therapeutics Market: Future Players in the Hepatitis B Therapeutics Market 28
7.1 Introduction 28
7.2 Bristol-Myers Squibb 28
7.2.1 Overview 28
7.2.2 Business Description 29
7.2.3 Infectious Disease Portfolio 30
7.2.4 Hepatitis B Therapeutics Product Portfolio 30
7.3 Gilead Sciences, Inc. 31
7.3.1 Overview 31
7.3.2 Business Description 31
7.3.3 Infectious Disease Portfolio 32
7.3.4 Hepatitis B Product Portfolio 32
7.4 Hoffmann-La Roche Ltd 33
7.4.1 Overview 33
7.4.2 Business Description 33
7.4.3 Infectious Disease Portfolio 34

8 Hepatitis B Therapeutics Market: Appendix 35
8.1 Definitions 35
8.2 Scope of Pipeline Research 35
8.3 Abbreviations 35
8.4 Research Methodology 36
8.4.1 Coverage 36
8.4.2 Secondary Research 36
8.4.3 Forecasting 37
8.4.4 Primary Research 40
8.4.5 Expert Panels 40
8.5 Contact Us 40
8.6 Disclaimer 40
8.7 Sources 41

List of Table


Table 1: Hepatitis B Therapeutics, Global, Market Revenue ($m), 20012009 7
Table 2: Hepatitis B Therapeutics, Global, Market Forecast ($m), 20092017 7
Table 3: Major Marketed Product in the Hepatitis B Therapeutics Market, 2010 18
Table 4: Hepatitis B Therapeutics Promising Drugs Under Clinical Development, 2010 21
Table 5: Hepatitis B Therapeutics Phase III Clinical Pipeline, 2010 24
Table 6: Hepatitis B Therapeutics Phase II Clinical Pipeline, 2010 25
Table 7: Hepatitis B Therapeutics Phase I Clinical Pipeline, 2010 25
Table 8: Hepatitis B Therapeutics Preclinical Pipeline, 2010 26
Table 9: Discontinued Drugs for Hepatitis B, 2010 26
Table 10: Bristol-Myer Squibb Infectious Disease and Hepatitis B Therapeutics Pipeline, 2010 30
Table 11: Gilead Sciences Inc. Infectious Disease and Hepatitis B Therapeutics Pipeline, 2010 32
Table 12: Hoffman-La Roche Ltd. Infectious Disease and Hepatitis B Therapeutics Pipeline, 2010 34

List of Chart


Figure 1: Hepatitis B Therapeutics, Global, Market Revenue ($m), 20012009 6
Figure 2: Hepatitis B Therapeutics, Global, Market Forecast ($m), 20092017 7
Figure 3: Opportunity and Unmet Need in the Hepatitis B Therapeutics Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Hepatitis B, 2010 12
Figure 5: Technology Trends Analytic Framework of the Hepatitis B Therapeutics Pipeline, 2010 20
Figure 6: Technology Trends Analytic Framework of Hepatitis B Therapeutics Pipeline, Description, 2010 20
Figure 7: Hepatitis B Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 23
Figure 8: Hepatitis B Therapeutics Pipeline by Phases of Clinical Development, 2010 24
Figure 9: Implications for Future Market Competition in the Hepatitis B Therapeutics Market, 2010 27
Figure 10: Hepatitis B Therapeutics Market Clinical Pipeline by Company, 2010 28
Figure 11: GlobalData Market Forecasting Model 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *